معرفی
Pablo Peña serves as a Research Engineer and Associate Researcher within the Department of Clinical Genetics at Lund University, specifically contributing to targeted therapies in leukemia research at the Lund University Cancer Centre (LUCC). His work spans multiple research groups focused on clinical genetics and cancer biology.
His research interests center on leukemia pathogenesis with particular emphasis on acute myeloid leukemia (AML) and B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Dr. Peña investigates metabolic plasticity in leukemia cells, single-cell genomic approaches to identify therapeutic vulnerabilities, and novel targets such as IL1RAP and C3AR in cancer therapy. His work bridges basic science with translational applications, focusing on how metabolic and genomic mechanisms can be exploited for therapeutic benefit.
Analysis of his publication record reveals a strong focus on molecular mechanisms in leukemia, with recent work exploring metabolic inhibitors, genomic vulnerabilities in specific leukemia subtypes, and the tumor microenvironment's role in disease progression. His research demonstrates interdisciplinary integration of genomics, metabolism, and immunology to develop novel therapeutic approaches.
Dr. Peña actively collaborates with multiple research groups across Lund University, contributing to projects that have garnered significant attention with multiple publications being picked up by news outlets and receiving substantial readership on academic platforms like Mendeley.
